/daily ·09 SEPT 2026 ·WEDNESDAY ·2 MIN READ ·6 STORIES

What the Studies Found This Week

Semaglutide extends female mouse lifespan, growth hormone timing shapes longevity, and a massive study complicates the exercise-dementia story.

01 / The Day

WEDNESDAY 09 SEPT 2026, ranked

Semaglutide Extended Lifespan in Female Mice When Given Late in Life

A study published in Nature found that semaglutide — a GLP-1 receptor agonist — extended median lifespan by approximately 18% in female mice when treatment began at 18 months of age (roughly equivalent to late middle age in humans), with no significant effect observed in male mice in the same cohort.

Female mice showed median lifespan extension of ~18%; male mice showed no statistically significant effect
Mechanism hypothesised to involve reduced adipose inflammation and altered metabolic signalling rather than weight loss alone
Study is preclinical; mouse lifespan interventions frequently do not translate to humans

Why it mattersThe sex-specific effect is the most scientifically novel finding — if replicated, it raises questions about whether GLP-1 trials need sex-stratified longevity endpoints.

01 nature.com↗

Study: Halting Growth Hormone in Middle-Aged Mice Extended Their Lifespan

Researchers showed that suppressing growth hormone signalling in mice beginning at middle age — rather than from birth, as in earlier Ames dwarf studies — was sufficient to produce significant lifespan extension, narrowing the window during which growth hormone reduction must occur to have an effect.

Prior research required growth hormone suppression from birth; this study shows mid-life intervention is sufficient in mice
Lifespan extension was approximately 15% in the treated cohort
Findings support the hypothesis that growth hormone drives ageing-related pathology, not just developmental trade-offs

Why it mattersEstablishing that mid-life intervention is sufficient — rather than requiring lifelong suppression — is a mechanistically important step toward any translational application.

02 lifespan.io↗

Large Study Finds Physical Activity Has Opposite Effects on Dementia Risk Depending on Timing

A study of over 500,000 UK Biobank participants found that vigorous physical activity was associated with reduced dementia risk in midlife but, paradoxically, higher self-reported physical activity in the five years before diagnosis was associated with increased risk — an effect attributed to reverse causality, where early disease symptoms drive behavioural change.

Midlife vigorous activity (ages 40–60) was associated with 28% lower dementia risk over follow-up
Late-life activity increase was associated with elevated risk, likely reflecting prodromal dementia driving changes in behaviour
Authors recommend that future studies use biomarker-confirmed disease onset to separate cause from consequence

Why it mattersThe reversal effect has practical implications for how observational studies report exercise-dementia links — several widely-cited papers may have their late-life findings confounded.

03 psypost.org↗

Proteomic Age Clocks Predict Mortality Risk Independently of Chronological Age

An analysis of multiple proteomics-based biological age clocks found that individuals whose proteomic age exceeded their chronological age by more than seven years had significantly elevated all-cause mortality risk over a 10-year follow-up, with the effect independent of established clinical risk factors.

Three independent proteomic clocks showed concordant mortality signal when biological age exceeded chronological age by 7+ years
Effect persisted after adjustment for smoking, BMI, diabetes status, and cardiovascular disease history
Proteomic ageing acceleration was not uniformly correlated with subjective health perception — many high-risk individuals rated their health as good

Why it mattersMortality prediction independent of established risk factors suggests proteomic clocks capture biological ageing processes that clinical measures miss.

04 fightaging.org↗

Engineered Exosomes Show Efficacy in Alzheimer's Mouse Model

A study demonstrated that exosomes engineered to carry amyloid-clearing enzymes crossed the blood-brain barrier and reduced amyloid plaque burden in a mouse model of Alzheimer's disease, outperforming direct enzyme injection in both plaque reduction and tolerability.

Exosomes are naturally occurring extracellular vesicles; engineering them for drug delivery exploits their ability to cross the blood-brain barrier
Plaque burden was reduced by ~40% compared to controls; the approach caused no detectable hepatotoxicity
Study is preclinical; blood-brain barrier models differ substantially between mice and humans

Why it mattersBlood-brain barrier penetration is the central delivery challenge for Alzheimer's therapeutics; exosome-based delivery could bypass it without the immunogenicity risks of viral vectors.

05 fightaging.org↗

Study: Associative Memory Declines Significantly by Age 50

A cross-sectional study of 12,000 adults found that the ability to form and retrieve associations between unrelated items — a key component of episodic memory — showed a statistically significant decline beginning in the early 50s, earlier than previously characterised by standard memory batteries.

Associative memory dropped detectably from age 53 onward; working memory showed a later and shallower decline trajectory
Decline was observed even when controlling for processing speed, suggesting it is not merely a speed artefact
Authors note that standard clinical memory tests are insensitive to associative decline at subclinical stages

Why it mattersIf associative memory declines in the early 50s — earlier than clinical tools detect — interventions targeting memory preservation may need to start earlier than current guidance suggests.

06 fightaging.org↗

Be subscriber #013 the weekly ten, every friday by email · no spam · unsubscribe anytime

Past days

The Daily Archive

/MON 14 SEPTThe SASP Dial /FRI 11 SEPTThe Senolytic Score /WED 09 SEPTWhat the Studies Found This Week /MON 07 SEPTAge is personal; centenarians deliver; Alzheimer's gets a blood test /FRI 04 SEPTLongevity — Friday 4 September /WED 02 SEPTWednesday Tissue Atlas /MON 31 AUGCellular Mechanisms, Measured /FRI 28 AUGExercise in a Dish, Inflammaging Mapped, and a Million-Person Gene Hunt /WED 26 AUGCascades, Clocks, and the Cheapest Dementia Intervention /MON 24 AUGLongevity — Mon 24 Aug 2026 /FRI 21 AUGThe immune systems of the very old /WED 19 AUGExercise in a pill, a gut microbiome review, and the senolytic biomarker gap /MON 17 AUGBrains, Exomes and a Cocktail /FRI 14 AUGWhat the Clocks Are Actually Measuring /WED 12 AUGInflammation, isolation, and the stem cells in your gut /MON 10 AUG350 papers on protein, 20 clinical trials, and a ceiling made of DNA /FRI 07 AUGFirst mRNA flu vaccine; tau finds a second way to harm /WED 05 AUGSenolytics, centenarian microbes, and a protein that poisons aging brains /MON 03 AUGProtein, lifespan ceilings, and uneven clocks /FRI 31 JULBlood proteins predict liver disease 16 years early /WED 29 JULWednesday, 29 July — Clocks, guts, heat